FDA Clears C2N's PrecivityAD2 Alzheimer's Blood Test for Ages 40+

The FDA cleared C2N Diagnostics’ PrecivityAD2 Alzheimer’s blood test for use in adults aged 40 and older showing cognitive impairment signs, marking it as the first such FDA-cleared test for this younger symptomatic group. The test offers high predictive accuracy using mass spectrometry to identify amyloid pathology and aims to enable earlier diagnosis and clinical trial participation.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 13 sources have reported it between 20 Aug 2026 and 26 Sep 2026.